Literature DB >> 10667581

Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.

T Habuchi1, T Suzuki, R Sasaki, L Wang, K Sato, S Satoh, T Akao, N Tsuchiya, N Shimoda, Y Wada, A Koizumi, J Chihara, O Ogawa, T Kato.   

Abstract

Recent studies have suggested that vitamin D is an important determinant of prostate cancer risk and inherited polymorphisms in the 3'-untranslated region (3'UTR) of the vitamin D receptor (VDR) gene are associated with the risk and progression of prostate cancer. This study was conducted to explore the association of VDR gene polymorphisms with prostate cancer risk in Japanese men who are considered to be much less influenced by environmental risk factors for prostate cancer. We studied 222 prostate cancer patients, 209 benign prostatic hyperplasia (BPH) patients, 128 male controls who were over 60 years old and without any evidence of prostate cancer or BPH, and 198 female controls. A PCR-RFLP method was used to determine three VDR gene polymorphisms in the 3'UTR characterized by restriction enzymes BsmI, ApaI and TaqI. In the BsmI polymorphism, heterozygosity or homozygosity for the absence of the BsmI restriction site was associated with one-third the risk of prostate cancer (P < 0.0001; odds ratio, 3.31; 95% confidence interval, 2.05-5.32) and with one-half the risk of BPH (P < 0.005; odds ratio, 2.07; 95% confidence interval, 1.33-3.22) compared with the male controls. The TaqI and ApaI polymorphisms did not show any significant association with either prostate cancer or BPH. The results indicate that the BsmI polymorphism in the VDR gene plays a significant role in protection against prostate cancer and BPH. Because of the racial difference in the strength of the linkage disequilibrium between the three polymorphisms, additional studies are required to apply the present results to other racial-ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667581

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

2.  Vitamin D receptor gene polymorphisms in patients with urolithiasis.

Authors:  Sezgin Gunes; Cenk Yucel Bilen; Nurten Kara; Ramazan Asci; Hasan Bagci; Ali Faik Yilmaz
Journal:  Urol Res       Date:  2006-01-06

3.  Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects.

Authors:  Zhan Guo; Jianguo Wen; Quancheng Kan; Shuman Huang; Xianghua Liu; Ning Sun; Zhenzhen Li
Journal:  Tumour Biol       Date:  2013-06-27

4.  [Association of vitamin D receptor gene polymorphisms with susceptibility to bone and joint tuberculosis in Chinese Han population].

Authors:  Jia-Wei Zhang; Qiang Zhang; Dong-Bin Qu; Zhen Lin; Xue-Ming Ma; Xin Zhong; Chao-Hui Sang; Xu-Shi Chen; Zu-Kun Song; Piao Huang; Jian-Ming Jiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

5.  TaqI polymorphism of VDR gene contributes to breast cancer risk.

Authors:  Hua Wang; Wenjian Wang; Dongjie Yang; Shenming Wang
Journal:  Tumour Biol       Date:  2013-08-01

6.  Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese.

Authors:  Jie Liu; Bao Song; Xueli Bai; Wenjian Liu; Zengjun Li; Jialin Wang; Yan Zheng; Zhehai Wang
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

7.  Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk.

Authors:  Xian-Tao Zeng; Qi-Sheng Yao; Hong Weng; Sheng Li; Jing-Yu Huang; Xing-Huan Wang
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

8.  Vitamin D receptor gene polymorphism in hypercalciuric children.

Authors:  Oğuz Söylemezoğlu; Ozan Ozkaya; Sevim Gönen; Müge Misirlioğlu; Süleyman Kalman; Necla Buyan
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

9.  The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.

Authors:  Sara Marchiani; Lorella Bonaccorsi; Pietro Ferruzzi; Clara Crescioli; Monica Muratori; Luciano Adorini; Gianni Forti; Mario Maggi; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-17       Impact factor: 4.553

10.  Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101).

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.